We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCGN icon
76
Ocugen
OCGN
$420M
$954K 0.06%
8,028
-10,045
-56% -$1.13M
SLS icon
77
SELLAS Life Sciences
SLS
$1.98B
$953K 0.06%
1,801
+38
+2% +$25.1K
GBT
78
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$935K 0.06%
301
-369
-55% -$10.4K
EGLT
79
DELISTED
Egalet Corporation
EGLT
$923K 0.06%
+721,050
New +$964K
XENE icon
80
Xenon Pharmaceuticals
XENE
$6.28B
$907K 0.06%
307,600
-3,208
-1% -$9.93K
STML
81
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
$890K 0.06%
802
-418
-34% -$3.93K
SIOX
82
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$874K 0.06%
159
-443
-74% -$74.7K
SGMO
83
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$863K 0.06%
575
– –
CHRN
84
ChronoScale Holdings
CHRN
$2.94B
$850K 0.06%
+3,122
New +$1.11M
SRRA
85
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$827K 0.05%
13,339
-28,223
-68% -$1.66M
FLXN
86
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$825K 0.05%
341
-414
-55% -$9.73K
TPST icon
87
Tempest Therapeutics
TPST
$13.9M
$781K 0.05%
188
+14
+8% +$59.8K
FOLD
88
PUT
DELISTED
Amicus Therapeutics
FOLD
$754K 0.05%
500
-2,182
-81% -$28.9K
SPHS
89
DELISTED
Sophiris Bio, Inc.
SPHS
$716K 0.05%
333,641
-24,151
-7% -$50K
FLXN
90
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
$706K 0.05%
292
-377
-56% -$8.86K
FOCL
91
PUT
EDAP TMS S.A.
FOCL
$227M
$663K 0.04%
2,224
+138
+7% +$414
ICPT
92
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$580K 0.04%
+100
New +$10.8K
XYLO
93
DELISTED
Xylo Technologies
XYLO
$578K 0.04%
1,613
-130
-7% -$44.4K
APDNW
94
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$575K 0.04%
857,768
-1,531,537
-64% -$731K
RIBT
95
DELISTED
RiceBran Technologies
RIBT
$575K 0.04%
44,203
-482
-1% -$5.18K
VXZ
96
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$551K 0.04%
26,500
– –
KRYS icon
97
Krystal Biotech
KRYS
$10.7B
$534K 0.03%
+53,558
New +$540K
DMK
98
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$524K 0.03%
+1,434
New +$509K
CDTX
99
DELISTED
Cidara Therapeutics
CDTX
$521K 0.03%
3,215
-3,035
-49% -$432K
OPGN
100
DELISTED
OpGen, Inc
OPGN
$514K 0.03%
17
+6
+55% +$192K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.